AZN - AstraZeneca PLC
| Previous Close | 42.90 |
| Open | 42.87 |
| Bid | 42.76 x 2200 |
| Ask | 42.78 x 800 |
| Day's Range | 42.72 - 43.12 |
| 52 Week Range | 35.30 - 45.69 |
| Volume | 3,653,464 |
| Avg. Volume | 3,147,265 |
| Market Cap | 111.366B |
| Beta (3Y Monthly) | 0.43 |
| PE Ratio (TTM) | 49.96 |
| EPS (TTM) | 0.86 |
| Earnings Date | N/A |
| Forward Dividend & Yield | 1.40 (3.26%) |
| Ex-Dividend Date | 2019-08-08 |
| 1y Target Est | 46.14 |
- Zacks
Glaxo's Asthma Drug Nucala Gets FDA Nod for Pediatric Use
Glaxo's (GSK) asthma medicine, Nucala gets FDA approval for use in pediatric patient population.
- Zacks
Pharma Stock Roundup: Pipeline/Regulatory Updates From GSK, PFE & Others
Glaxo's (GSK) Nucala gets FDA nod for use in kids. Pfizer (PFE), Allergan (AGN) & Roche (RHHBY) give regular pipeline/regulatory updates.
- Zacks
Roche Reports Positive Data on Tecentriq & NMOSD Drug (Revised)
Roche's (RHHBY) immuno-oncology drug, Tecentriq, meets the primary goal in a late-stage study in NSCLC patients. Also, the company reports positive data on its NMOSD drug in a phase III study.
- GuruFocus.com
Gilead Tops List of Most Innovative Drug Companies
Index ranks ability of pharma companies to bring drugs from early testing to market and make them successful Continue reading...
- Zacks
Roche (RHHBY) Reports Positive Data on Tecentriq & MS Drug
Roche's (RHHBY) immuno-oncology drug, Tecentriq, meets the primary goal in a late-stage study in NSCLC patients. Also, the company reports positive data on its MS drug in a phase III study.
- American City Business Journals
East Bay company eyes first drug approval after decade-long journey
The company has burned through $400 million, laid off employees and lost two Big Pharma partnerships, but now it is near an FDA drug approval for people with a debilitating bowel disorder.
- GuruFocus.com
Leaner Pfizer Positioned to Boost R&D Output
Company’s recent decisions will enable it to concentrate on building core business Continue reading...
- Zacks
AVEO Surges on Favorable Updated OS Results on RCC Drug
AVEO posts positive updated results from the second prespecified overall survival analysis of Fotivda for treating highly refractory metastatic renal cell carcinoma. Stock up more than 30%.
- Zacks
Bristol-Myers' (BMY) Opdivo Shows Long-Term Survival Benefit
Bristol-Myers' (BMY) Opdivo continues to experience long-term OS benefit as demonstrated by the long-term pooled efficacy and safety results in patients with previously-treated NSCLC.
- Zacks
Lexicon (LXRX) Settles With Sanofi for $260M, Shares Rally
Lexicon Pharmaceuticals (LXRX) settles with Sanofi related to termination of their alliance for development of Zynquista in type I and type II diabetes.
- Zacks
4 Big Drugmakers Boasting Impressive Oncology Pipelines
We discuss four pharma giants, which possess the industry's strongest oncology pipeline portfolios.
- Simply Wall St.
Should You Buy AstraZeneca PLC (LON:AZN) For Its Dividend?
Today we'll take a closer look at AstraZeneca PLC (LON:AZN) from a dividend investor's perspective. Owning a strong...
- Zacks
ACADIA Surges on Early Success of Nuplazid Dementia Study
ACADIA Pharmaceuticals' (ACAD) Parkinson's psychosis drug, Nuplazid, meets primary endpoint earlier than expected in late-stage label expansion study evaluating it in patients with dementia-related psychosis.
- Business Wire
IMFINZI Is First Immunotherapy to Show Both Significant Survival Benefit and Improved, Durable Responses in Extensive-Stage Small Cell Lung Cancer
In the Phase III CASPIAN trial IMFINZI at a fixed, convenient dose improved survival with either a cisplatin or carboplatin chemotherapy backbone
- Reuters
CORRECTED-AstraZeneca's Imfinzi prolongs survival in aggressive lung cancer
AstraZeneca's cancer treatment Imfinzi has been shown to prolong survival in a particularly aggressive type of lung cancer by close to three months, as the British drugmaker holds its ground in a crowded field against rival immunotherapy drugs. Patients in a reference group on chemotherapy only lived a median 10.3 months in the so-called Caspian trial, it said. "There is a wide recognition that in small cell lung cancer there is very much a need for new therapies," said Dave Fredrickson, head of the company's oncology business.
- Zacks
Novartis' Capmatinib Gets Breakthrough Therapy Tag From FDA
The FDA grants a Breakthrough Therapy status to Novartis' (NVS) capmatinib for the first-line treatment of patients with metastatic MET exon14 skipping-mutated non-small cell lung cancer.
- Zacks
Pharma Stock Roundup: AGN's Opioid Settlement, Line Extension Nod in EU for MRK, JNJ Drugs
Allergan (AGN) settles with two Ohio plaintiffs for $5 million. Merck's (MRK) Keytruda, Roche's (RHHBY) Tecentriq and J&J's (JNJ) Stelara get EU approval for expanded use.
- Zacks
Roche's Tecentriq Combo Gets EU Nod for Difficult Lung Cancer
The latest EU nod makes Roche's (RHHBY) immuno-oncology drug -- Tecentriq -- the first and only cancer immunotherapy approved for the initial treatment of ES-SCLC in Europe.
- Zacks
AstraZeneca's Tagrisso Gets Nod in China for First-Line NSCLC
AstraZeneca's (AZN) Tagrisso gets a marketing approval in China for the first-line treatment of advanced or metastatic non-small cell lung cancer in patients with tumors having EGFR mutations.
- Barrons.com
Podcast: Why Big Pharma Is Betting on a New Biotech Therapy
Host Alex Eule is joined by Josh Nathan-Kasiz to talk about one of biotech’s most promising treatments, mRNA therapy.
- Motley Fool
Is the FDA Out to Get This $2.9 Billion Diabetes Drug Class?
It’s rejected a pair of drugs in the last six months.
- Zacks
Vertex (VRTX) Inks All-Cash Deal to Acquire Semma for $950M
Vertex (VRTX) inks an all-cash deal to buy privately-held Semma Therapeutic. The acquisition will add pre-clinical type I diabetes candidates to its pipeline.
- American City Business Journals
5 things to know ahead of Viela Bio’s planned $150M IPO
It’s a pivotal moment for the MedImmune spinout, which has put the fate of its first prospective product in regulators' hands.
- Yahoo Finance
Companies to Watch: Roche gets more time for Spark deal, AstraZeneca shows promise in clinical trial, Snap get upgraded
Roche, Spark, AstraZeneca, Snap, Walmart and eBay are the companies to watch
- Bloomberg
AstraZeneca's Executive VP Sees Upside, As China's Government Speeds Up New Drug Approval
Sep.09 -- AstraZeneca PLC is betting on sales of its new drug to outweigh that of off-patient ones in China over the next five years amid Chinese regulator's expedited approval of new therapies to meet unmet medical demands. Leon Wang, it's executive vice president overseeing international markets, spoke exclusively to Selina Wang on "Bloomberg Daybreak: Asia.
